Mike Burgess

Mike Burgess is a seasoned professional in the field of translational medicine with extensive experience at Bristol Myers Squibb since November 2019, currently serving as Senior Vice President and Head of Translational Medicine. Burgess oversees the strategy and execution of translational research for late development clinical pipelines across several therapeutic areas, including oncology and hematology. Prior roles at Bristol Myers Squibb include Vice President and Executive Director in Early Clinical Development, focusing on Immuno-Oncology and Cell Therapy. Additional experience includes leadership roles at Celgene, academic positions at UCSF as Assistant Clinical Professor, and a history of involvement in clinical instruction and research in hematology/oncology. Burgess holds an MD from the David Geffen School of Medicine at UCLA and a PhD in Molecular Biology from UCLA, complemented by a BA in Molecular and Cell Biology from UC Berkeley.